Helminen A - Search Results

1

Validity assessment of a social support index.

Helminen A, Halonen P, Rankinen T, Nissinen A, Rauramaa R. Helminen A, et al. Scand J Soc Med. 1995 Mar;23(1):66-74. doi: 10.1177/140349489502300112. Scand J Soc Med. 1995. PMID: 7784856

2

Carotid atherosclerosis in middle-aged men. Relation to conjugal circumstances and social support.

Helminen A, Rankinen T, Mercuri M, Rauramaa R. Helminen A, et al. Scand J Soc Med. 1995 Sep;23(3):167-72. doi: 10.1177/140349489502300306. Scand J Soc Med. 1995. PMID: 8602486

3

Social network in relation to plasma fibrinogen.

Helminen A, Rankinen T, Väisänen S, Rauramaa R. Helminen A, et al. J Biosoc Sci. 1997 Apr;29(2):129-39. doi: 10.1017/s0021932097001296. J Biosoc Sci. 1997. PMID: 9881125

4

Positive and negative life changes and LDL cholesterol.

Helminen A, Rankinen T, Halonen P, Väisänen S, Rauramaa R. Helminen A, et al. J Biosoc Sci. 1999 Apr;31(2):269-77. doi: 10.1017/s0021932099002692. J Biosoc Sci. 1999. PMID: 10333656

5

Relationship between changes in physical activity and plasma insulin during a 2.5-year follow-up study.

Rankinen T, Suomela-Markkanen T, Väisänen S, Helminen A, Penttilä I, Berg A, Bouchard C, Rauramaa R. Rankinen T, et al. Among authors: helminen a. Metabolism. 1997 Dec;46(12):1418-23. doi: 10.1016/s0026-0495(97)90141-4. Metabolism. 1997. PMID: 9439536

6

Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids.

Laine K, Anttila M, Helminen A, Karnani H, Huupponen R. Laine K, et al. Among authors: helminen a. Br J Clin Pharmacol. 1999 Mar;47(3):249-54. doi: 10.1046/j.1365-2125.1999.00891.x. Br J Clin Pharmacol. 1999. PMID: 10215747 Free PMC article. Clinical Trial.

7

Spectral analysis of heart rate variability as a quantitative measure of parasympatholytic effect--integrated pharmacokinetics and pharmacodynamics of three anticholinergic drugs.

Scheinin H, Helminen A, Huhtala S, Grönroos P, Bosch JA, Kuusela T, Kanto J, Kaila T. Scheinin H, et al. Among authors: helminen a. Ther Drug Monit. 1999 Apr;21(2):141-51. doi: 10.1097/00007691-199904000-00001. Ther Drug Monit. 1999. PMID: 10217331 Clinical Trial.

8

Lack of adverse interactions between concomitantly administered selegiline and citalopram.

Laine K, Anttila M, Heinonen E, Helminen A, Huupponen R, Mäki-Ikola O, Reinikainen K, Scheinin M. Laine K, et al. Among authors: helminen a. Clin Neuropharmacol. 1997 Oct;20(5):419-33. doi: 10.1097/00002826-199710000-00006. Clin Neuropharmacol. 1997. PMID: 9331518 Clinical Trial.

9

Bioavailability of dexmedetomidine after extravascular doses in healthy subjects.

Anttila M, Penttilä J, Helminen A, Vuorilehto L, Scheinin H. Anttila M, et al. Among authors: helminen a. Br J Clin Pharmacol. 2003 Dec;56(6):691-3. doi: 10.1046/j.1365-2125.2003.01944.x. Br J Clin Pharmacol. 2003. PMID: 14616431 Free PMC article. Clinical Trial.

10

Pharmacokinetics and safety of deramciclane during multiple oral dosing.

Kanerva H, Kilkku O, Helminen A, Rouru J, Scheinin M, Huupponen R, Klebovich I, Drabant S, Urtti A. Kanerva H, et al. Among authors: helminen a. Int J Clin Pharmacol Ther. 1999 Dec;37(12):589-97. Int J Clin Pharmacol Ther. 1999. PMID: 10599951 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

31 results

Search Page